Search Results - "Szlosarek, P."

Uveal Melanoma UK National Guidelines by Nathan, P, Cohen, V, Coupland, S, Curtis, K, Damato, B, Evans, J, Fenwick, S, Kirkpatrick, L, Li, O, Marshall, E, McGuirk, K, Ottensmeier, C, Pearce, N, Salvi, S, Stedman, B, Szlosarek, P, Turnbull, N

“…Abstract The United Kingdom (UK) uveal melanoma guideline development group used an evidence based systematic approach (Scottish Intercollegiate Guidelines…”
Get full text

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma by Syed, N, Langer, J, Janczar, K, Singh, P, Lo Nigro, C, Lattanzio, L, Coley, H M, Hatzimichael, E, Bomalaski, J, Szlosarek, P, Awad, M, O'Neil, K, Roncaroli, F, Crook, T

“…Arginine deprivation, either by nutritional starvation or exposure to ADI-PEG20, induces adaptive transcriptional upregulation of ASS1 and ASL in glioblastoma…”
Get full text

Rituximab in the treatment of pembrolizumab-induced myasthenia gravis by Crusz, S.M., Radunovic, A., Shepherd, S., Shah, S., Newey, V., Phillips, M., Lim, L., Powles, T., Szlosarek, P.W., Shamash, J., Rashid, S.

Get full text

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity by Wang, H, Lee, S, Nigro, C Lo, Lattanzio, L, Merlano, M, Monteverde, M, Matin, R, Purdie, K, Mladkova, N, Bergamaschi, D, Harwood, C, Syed, N, Szlosarek, P, Briasoulis, E, McHugh, A, Thompson, A, Evans, A, Leigh, I, Fleming, C, Inman, G J, Hatzimichael, E, Proby, C, Crook, T

“…Background: Novel prognostic biomarkers and therapeutic strategies are urgently required for malignant melanoma. Ecto-5-prime-nucleotidase ( NT5E ; CD73)…”
Get full text

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis by Delage, B, Luong, P, Maharaj, L, O’Riain, C, Syed, N, Crook, T, Hatzimichael, E, Papoudou-Bai, A, Mitchell, T J, Whittaker, S J, Cerio, R, Gribben, J, Lemoine, N, Bomalaski, J, Li, C-F, Joel, S, Fitzgibbon, J, Chen, L-T, Szlosarek, P W

“…Tumours lacking argininosuccinate synthetase-1 (ASS1) are auxotrophic for arginine and sensitive to amino-acid deprivation. Here, we investigated the role of…”
Get full text

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer by Lim, S L, Smith, P, Syed, N, Coens, C, Wong, H, van der Burg, M, Szlosarek, P, Crook, T, Green, J A

“…The Fanconi gene family has a role in DNA repair and inactivation of FANCF has been proposed as a mechanism of sensitisation to platinum chemotherapy. This…”
Get full text

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy by Carpentier, Josephine, Pavlyk, Luliia, Mukherjee, Uma, Hall, Peter E, Szlosarek, Peter W

“…Arginine deprivation has gained increasing traction as a novel and safe antimetabolite strategy for the treatment of several hard-to-treat cancers…”
Get full text

Synchronous melanoma and renal carcinoma: a clinicopathological study of five cases by Matin, R. N., Szlosarek, P., McGregor, J. M., Cerio, R., Harwood, C. A.

“…Summary An increased frequency of renal carcinoma in men with melanoma has been reported in population based‐studies. We report the clinicopathological…”
Get full text

The combination of the metabolism-based targeted therapies ADI-PEG20 and GC7 are a promising strategy for the treatment of malignant pleural mesothelioma by Carpentier, J., Szlosarek, P., Martin, S.A.

Get full text

Tumour necrosis factor alpha: a potential target for the therapy of solid tumours by Szlosarek, Peter W, Balkwill, Frances R

“…Tumour necrosis factor alpha (TNFalpha), named for its antitumour properties, was isolated almost 30 years ago. It is a vital member of the multifunctional TNF…”
Get more information

305 (PB293): Preclinical development of PLGA-encapsulated Disulfiram for treatment of malignant mesothelioma by Lakshmanan, Y., Butcher, K., Azar, K., Ireson, C., Jain, S., Wang, Y., Szlosarek, P., Kannappan, V., Weiguang, W.

Get full text

135 (PB123): MITOPE: Phase 2 evaluation of RSO-021, a novel mitochondrial PRX3 inhibitor, as a monotherapy and in combination with paclitaxel in patients with malignant pleural effusion due to mesothelioma or other advanced solid tumors by Naumov, G., Dulloo, S., Fennell, D., Lord, S., Thistlethwaite, F., Maskell, N., Popat, S., Blyth, K., Szlosarek, P., Aujayeb, A., Franks, K., Herrero, J., Cunniff, B., Duncan, J., Graham, P., Bexon, A., Spicer, J.

Get full text

A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma by Nicholson, S, Guile, K, John, J, Clarke, I A, Diffley, J, Donnellan, P, Michael, A, Szlosarek, P, Dalgleish, A G

“…We conducted a randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 (IL-2) as treatment for stage IV malignant melanoma. The…”
Get full text

Tumour necrosis factor-α as a tumour promoter by Szlosarek, Peter, Charles, Kellie A., Balkwill, Frances R.

“…It is becoming more evident that many aspects of tumour promotion arise from persistent and unresolving inflammation. One of the key molecules mediating the…”
Get full text

Potential applications of gene therapy in the patient with cancer by SZLOSAREK, P. W, DALGLEISH, A. G

“…The elderly population has much to gain from the advances of molecular medicine, although at present genetic pharmacology remains mostly at the conceptual…”
Get full text

Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel by Szlosarek, Piotr W, Lofts, Fiona J, Pettengell, Ruth, Carter, Paul, Young, Martin, Harmer, Clive

“…The rarity of endometrial stromal sarcoma (ESS) and its poor response to treatment provides fertile ground for investigational therapies. An accelerated…”
Get full text

Recent advances in palliative care. United Kingdom continues to lead in palliative care by Szlosarek, P W

Get full text

CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma by Hanna, G., Griffiths, G., Kirkpatrick, E.V., Cozens, K., Kalevras, M., Maishman, T., Danson, S., Lester, J., Ottensmeier, C., Steele, N., Szlosarek, P., Lord, J., Nye, M., Fennell, D.

Get full text

190 - CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma by Hanna, G., Griffiths, G., Kirkpatrick, E.V., Cozens, K., Kalevras, M., Maishman, T., Danson, S., Lester, J., Ottensmeier, C., Steele, N., Szlosarek, P., Lord, J., Nye, M., Fennell, D.

Get full text

Synchronous melanoma and renal carcinoma: a clinicopathological study of five cases: Melanoma and renal carcinoma by Matin, R. N., Szlosarek, P., McGregor, J. M., Cerio, R., Harwood, C. A.

Get full text